Skip to main content
. Author manuscript; available in PMC: 2017 Jul 14.
Published in final edited form as: Aliment Pharmacol Ther. 2014 May 11;40(1):93–104. doi: 10.1111/apt.12788

Figure 2.

Figure 2

This figure shows the fraction of patients becoming HDV RNA negative (red), HBsAg negative (black) or have ALT < 31 U/L (blue) during course of treatment out to 240 weeks.